Aspergillus fumigatus is a filamentous fungus known for its role in causing aspergillosis, which ranges from allergic reactions to severe invasive pulmonary diseases, particularly in immunocompromised individuals.
One of its critical virulence factors is Asp f1, a ribotoxin and major allergen that binds IgE antibodies in patients with allergic bronchopulmonary aspergillosis (ABPA).
Asp f1 is secreted during the active growth phase of the fungus, contributing to its pathogenicity by inhibiting protein synthesis in host cells and eliciting strong immune responses.
Due to its significant role in both immune response and fungal invasion, Asp f1 serves as an important biomarker for detecting invasive aspergillosis, with diagnostic tests for Asp f1 in blood and urine offering a non-invasive method for early detection and management of Aspergillus infections.
Aspergillus fumigatus is a species of filamentous fungus that plays important ecological roles but can also cause serious infections in humans.
Aspergillus fumigatus is a leading cause of aspergillosis, an infection ranging from allergic reactions to invasive pulmonary disease, particularly affecting immunocompromised individuals.
Early diagnosis, species identification, and appropriate antifungal therapy are crucial for effective treatment.
Aspergillus fumigatus is part of the genus Aspergillus, which includes over 250 species, many of which are pathogenic.
This species is characterized by bluish-green conidial heads and a high thermotolerance, allowing it to thrive in diverse environments, from soil and compost to decaying vegetation. It is highly prevalent due to its resilience and ability to produce numerous secondary metabolites.
A. fumigatus possesses several virulence factors, such as conidial melanin and gliotoxin, which help it evade host defenses.
It can grow at body temperature and survive in the host's nutrient-limited environment, making it a formidable pathogen in immunocompromised patients.
The fungus’ ability to produce ascospores, virulence factors, and its high thermotolerance contribute to its virulence.
Infections by A. fumigatus primarily affect the lungs but can disseminate to other organs, especially in immunocompromised patients.
The central nervous system is another common site highly affected by A. fumigatus. [7.]
Conditions include invasive aspergillosis (IA), allergic bronchopulmonary aspergillosis (ABPA), and chronic pulmonary aspergillosis. IA has a high fatality rate and is particularly severe in patients with weakened immune systems.
Acute invasive aspergillosis is a serious infection in immunocompromised patients, characterized by rapid progression, often resulting in high fatality rates.
In contrast, chronic Aspergillus infections typically affect patients with some degree of immune suppression and underlying lung diseases like chronic obstructive pulmonary disease (COPD), as well as those on long-term corticosteroids. It progresses slowly, leading to lung tissue damage or sinus problems over time.
Allergic aspergillosis, including Allergic Bronchopulmonary Aspergillosis (ABPA) and Allergic Fungal Sinusitis, are caused by type 1 or type 3 hypersensitivity reactions. ABPA, a pulmonary disease caused by hypersensitivity reactions to Aspergillus fumigatus allergens, commonly occurs in asthmatic and cystic fibrosis patients and causes bronchial obstruction, productive cough, wheezing, chest pain, fever, and malaise.
Allergic fungal sinusitis causes inflammation and obstruction without tissue invasion.
Accurate diagnosis involves a combination of morphological and genetic analyses, with galactomannan and (1,3)-β-D-glucan assays being commonly used. Certain antigens and virulence factors such as A. fumigatus Asp f 1 can also be tested.
Voriconazole is the preferred treatment for IA, supported by guidelines from the Infectious Diseases Society of America. [8.] Timely initiation of antifungal therapy is critical for improving patient outcomes.
Virulence factors of Aspergillus species include:
Biofilms protect Aspergillus from host defenses and antifungal treatments, promoting persistent and chronic infections, especially in immune-compromised individuals. [4.]
Lipases degrade lipids, aiding in nutrient acquisition and tissue invasion by breaking down host cell membranes. [4.]
α-Amylase breaks down carbohydrates, providing energy and aiding in colonization of host tissues. [4.]
Pectinases degrade pectin, a polysaccharide found in plant cell walls, facilitating the invasion of plant-derived substrates. [4.]
Proteinases degrade proteins, helping the fungus to invade host tissues and evade immune responses. [4.]
Phospholipases break down phospholipids in cell membranes, aiding in host cell lysis and tissue penetration. [4.]
Haemolysins lyse red blood cells, releasing iron and other nutrients vital for fungal growth and survival in the host. [4.]
Catalases (Cat1p and Cat2p) and superoxide dismutases (MnSOD and Cu, ZnSOD) produced by Aspergillus neutralize the immune system’s offenses. [6.]
These virulence factors confuse and impede the immune response, while promoting cell invasion and death. [6.]
Asp f I is part of a family of ribotoxins produced by Aspergillus species. They are potent inhibitors of protein synthesis in eukaryotic cells, as well as potent stimulators of allergenicity. The family of ribotoxins includes mitogillin, restrictocin, and α-sarcin, and Asp f1 to Asp f23. [6.]
A. fumigatus Asp f1, a ribotoxin secreted by Aspergillus fumigatus, plays a critical role in the pathogenicity of this fungus.
It is a ribosome-inactivating protein (RIP) that leads to the inhibition of eukaryotic protein synthesis.
It possesses allergenic, cytotoxic and invasive properties. [2., 6.] Regarding its massive allergenic response, the A. fumigatus Asp f 1 allergen stimulates both humoral and cell-mediated immune responses in ABPA. [5.]
Asp f1 is produced during the active growth phase of A. fumigatus, specifically during hyphal development. Its production ceases once hyphal growth stops and sporulation begins.
This ribotoxin is secreted into the environment, contributing to the fungus's invasive capabilities by damaging host cells.
Asp f1 is a major IgE-binding allergen associated with conditions such as allergic bronchopulmonary aspergillosis (ABPA), aspergilloma, and cystic fibrosis with complications of ABPA. It can elicit strong antibody responses in individuals exposed to A. fumigatus. [1., 3.]
It shares a high degree of similarity with other ribotoxins such as restrictocin, mitogillin, and α-sarcin from various Aspergillus species. [1.]
Due to its secretion during active fungal growth, Asp f1 serves as an ideal biomarker for detecting invasive pulmonary aspergillosis (IPA). Testing for Asp f1 in urine is a non-invasive and effective way to assess for Apergillus infection. [2.]
Often, blood tests are run to assess for antibodies against the infectious agent A. fumigatus. Urine tests may also be run to assess for the presence of specific toxins or virulence factors, including Aspergillus fumigatus Asp f 1.
Sputum or bronchoalveolar lavage may also be assessed for the presence of Aspergillus fumigatus.
Blood tests typically require a venipuncture, while urine samples can be collected from the comfort of home.
While special preparation may not be required, it is essential to consult with the ordering provider prior to sample collection.
A. fumigatus Asp f 1 is a virulence factor associated with infection by the A. fumigatus fungus. Ideal levels are undetectable, or extremely low, in the absence of symptoms.
The presence of symptoms, even with extremely low levels on testing, may signify the need for further assessment including additional attesting for the presence of other molds, fungi, mycotoxins, or infectious agents.
Elevated levels of A. fumigatus may indicate an allergic sensitization, or an active infection. An infection signals a need for eradication of the A. fumigatus organism; additional assessment for the presence of co-infections may be warranted.
An individual with elevated levels of this biomarker may need additional assessment of immune function and may require additional immune support.
Click here to compare testing options and order tests for Aspergillus fumigatus levels.
[1.] Arruda LK, Platts-Mills TA, Fox JW, Chapman MD. Aspergillus fumigatus allergen I, a major IgE-binding protein, is a member of the mitogillin family of cytotoxins. J Exp Med. 1990 Nov 1;172(5):1529-32. doi: 10.1084/jem.172.5.1529. PMID: 2230656; PMCID: PMC2188668.
[2.] Davies G, Singh O, Prattes J, Hoenigl M, Sheppard PW, Thornton CR. Aspergillus fumigatus and Its Allergenic Ribotoxin Asp f I: Old Enemies but New Opportunities for Urine-Based Detection of Invasive Pulmonary Aspergillosis Using Lateral-Flow Technology. J Fungi (Basel). 2020 Dec 31;7(1):19. doi: 10.3390/jof7010019. PMID: 33396482; PMCID: PMC7823411.
[3.] Kurup VP, Banerjee B, Murali PS, Greenberger PA, Krishnan M, Hari V, Fink JN. Immunodominant peptide epitopes of allergen, Asp f 1 from the fungus Aspergillus fumigatus. Peptides. 1998;19(9):1469-77. doi: 10.1016/s0196-9781(98)00113-2. PMID: 9864052.
[4.] Raksha, Singh G, Urhekar AD. Virulence Factors Detection in Aspergillus Isolates from Clinical and Environmental Samples. J Clin Diagn Res. 2017 Jul;11(7):DC13-DC18. doi: 10.7860/JCDR/2017/24055.10211. Epub 2017 Jul 1. PMID: 28892890; PMCID: PMC5583800.
[5.] Raval KM, Ghormade V, Rajamohanan PR, Choudhary H, Rudramurthy SM, Chakrabarti A, Paknikar K. Development of a nano-gold immunodiagnostic assay for rapid on-site detection of invasive aspergillosis. J Med Microbiol. 2019 Sep;68(9):1341-1352. doi: 10.1099/jmm.0.001040. PMID: 31355743.
[6.] Rementeria A, López-Molina N, Ludwig A, Vivanco AB, Bikandi J, Pontón J, Garaizar J. Genes and molecules involved in Aspergillus fumigatus virulence. Rev Iberoam Micol. 2005 Mar;22(1):1-23. doi: 10.1016/s1130-1406(05)70001-2. PMID: 15813678.
[7.] Sugui JA, Kwon-Chung KJ, Juvvadi PR, Latgé JP, Steinbach WJ. Aspergillus fumigatus and related species. Cold Spring Harb Perspect Med. 2014 Nov 6;5(2):a019786. doi: 10.1101/cshperspect.a019786. PMID: 25377144; PMCID: PMC4315914.
[8.] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(3):327-360. doi:https://doi.org/10.1086/525258